RE:RE:Hi FrancineHi everyone and happy new year.
Hopefully 2021 will be better than 2020 for Acasti.
Obviously, since 40% of patients were not HTG at week 0, it was mathematically impossible to reach stastical significance of >20%.
Management is reponsible for this and they should have known that food and exercice have impact on TG level. This being said, what is the future for Acasti.
With 43% reduction for very HTG, Capre did very well and its not the act of god.
For the future, the value of the company is linked to all the secondary end points, the most important one is the diabetic angle.
I do believe that management have those secondary end points in hands.
There was well over 1,000,000,0000 shares traded over the last 20 business days for around 96,000,000 shares, this mean that all shareholders sold their shares 10 times ... it does not make any sense for my point of view.
With $10M-$13M cash in hands and around 100,000,000$ of tax losses carry foward, and a good IP, I would think that Acasti is an easy target for a big pharma company.
I didn't sold any share and I am waiting to see who is the buyer or the future partner.
We will know with the 13k or 13F shortly who is behind all this. I think we will have better understanding is the next 5-45 days. there is no nead to sell, except if you bought in the 30 cents range.
Enjoy the ride.